PMC6426764_01
(A) Breakdown of the patient cohort treated with zFOLFIRI at Fox Chase Cancer Center leading to the 17 mCRC patients who had prior bevacizumab plus FOLFIRI. Details of tumor mutational status, some prior therapies, and disease control while on zFOLFIRI is shown. (B) Cohort selection of mCRC zFOLFIRI from patients in the Flatiron Health network. Out of the entire cohort of 18,877 patients diagnosed with CRC cancer, filters were applied to define a Flatiron Health cohort that most closely matched the FCCC cohort. Patients were filtered by increasingly strict criteria and excluded if they did not meet the criteria as defined in each row.
fonc-09-00142-g0001.jpg
PMC6426764_01_fonc-09-00142-g0001.jpg
F1
The CEA trends observed in this patient showed reduction during both zFOLFIRI treatment periods (Supplementary Figure 1).
PMC6426764_02
PMC6426764_03
PMC6426764_04
PMC6426764_05
PMC6426764_06